Medigen Biotechnology Corporation
3 clinical trials · Sponsor
◉ Watch Medigen Biotechnology Corporation
| Record | Firm | Date |
|---|---|---|
| Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients (NCT06730009) | Medigen Biotechnology Corporation | 2024-10-21 |
| A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study (NCT05394714) | Medigen Biotechnology Corporation | 2022-03-10 |
Track Medigen Biotechnology Corporation automatically
Every clearance here is in the API, with alerts when new ones post.